Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Rating) was the target of significant short-term interest growth in the month of June. As of June 30, there were short interests totaling 10,210,000 shares, a growth of 64.7% from the total of 6,200,000 shares as of June 15. Based on an average daily volume of 1,830,000 shares, the short interest rate is currently 5.6 days.
A Wall Street analyst gives his opinion
Separately, Craig Hallum began covering Xeris Biopharma in a research report on Thursday, April 28. They issued a “buy” rating and a price target of $6.50 on the stock.
Price performance of Xeris Biopharma
Shares of Xeris Biopharma opened at $1.43 on Friday. The company has a quick ratio of 2.42, a current ratio of 2.67 and a debt ratio of 1.43. The company has a market cap of $193.81 million and a price-earnings ratio of -0.97. Xeris Biopharma has a 52 week minimum of $1.25 and a 52 week maximum of $3.68. The stock’s 50-day simple moving average is $1.84 and its 200-day simple moving average is $2.23.
Xeris Biopharma (NASDAQ:XERS – Get Rating) last reported results on Wednesday, May 11. The company reported ($0.25) EPS for the quarter, missing analyst consensus estimates of ($0.24) by ($0.01). The company posted revenue of $22.07 million in the quarter, compared to $22.92 million expected by analysts. Xeris Biopharma posted a negative return on equity of 258.57% and a negative net margin of 217.81%. As a group, analysts expect Xeris Biopharma to post -0.83 earnings per share for the current fiscal year.
Insider buying and selling at Xeris Biopharma
Separately, insider Paul R. Edick bought 100,000 shares of the company in a trade on Thursday, May 12. The shares were acquired at an average price of $1.40 per share, with a total value of $140,000.00. Following the completion of the acquisition, the insider now owns 1,508,064 shares of the company, valued at approximately $2,111,289.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, accessible via this hyperlink. 5.17% of the shares are currently held by company insiders.
Institutional investors weigh in on Xeris Biopharma
A number of hedge funds have recently changed their positions in XERS. Running Point Capital Advisors LLC purchased a new stake in Xeris Biopharma stock in the first quarter worth approximately $26,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Xeris Biopharma during the first quarter, valued at approximately $28,000. CTC Capital Management LLC acquired a new stake in Xeris Biopharma during the first quarter worth approximately $30,000. Whitener Capital Management Inc. acquired a new stake in Xeris Biopharma during the first quarter valued at approximately $30,000. Finally, Raymond James & Associates acquired a new stake in Xeris Biopharma during the fourth quarter valued at approximately $33,000. 18.72% of the shares are currently held by hedge funds and other institutional investors.
About Xeris Biopharma
(Get an assessment)
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for endocrinology, neurology and gastroenterology patient populations. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycaemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proven to treat endogenous hypercortisolemia in adult patients with Cushing’s syndrome.
Get news and reviews for Xeris Biopharma Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Xeris Biopharma and related companies with MarketBeat.com’s free daily email newsletter.